BioCardia (NASDAQ:BCDA) Announces Quarterly Earnings Results

BioCardia (NASDAQ:BCDA) released its quarterly earnings results on Thursday. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01, FiscalAI reports.

BioCardia Price Performance

Shares of NASDAQ:BCDA traded down $0.10 on Thursday, reaching $0.83. The company’s stock had a trading volume of 288,420 shares, compared to its average volume of 996,821. BioCardia has a 52-week low of $0.66 and a 52-week high of $1.80. The stock has a market capitalization of $12.50 million, a P/E ratio of -1.29 and a beta of 0.69. The stock’s 50-day moving average is $1.02 and its two-hundred day moving average is $1.06.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research upgraded shares of BioCardia from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Thursday, October 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of BioCardia in a research report on Monday, August 24th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $25.00.

About BioCardia

BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy. BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.